Exact Therapeutics AS (OSL:EXTX) Debt-to-Equity : 0.03 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Exact Therapeutics AS Debt-to-Equity?

Exact Therapeutics AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr0.55 Mil. Exact Therapeutics AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr0.65 Mil. Exact Therapeutics AS's Total Stockholders Equity for the quarter that ended in Dec. 2023 was kr45.10 Mil. Exact Therapeutics AS's debt to equity for the quarter that ended in Dec. 2023 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Exact Therapeutics AS's Debt-to-Equity or its related term are showing as below:

OSL:EXTX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.02 Max: 0.03
Current: 0.03

During the past 7 years, the highest Debt-to-Equity Ratio of Exact Therapeutics AS was 0.03. The lowest was 0.00. And the median was 0.02.

OSL:EXTX's Debt-to-Equity is ranked better than
82.16% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs OSL:EXTX: 0.03

Exact Therapeutics AS Debt-to-Equity Historical Data

The historical data trend for Exact Therapeutics AS's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Therapeutics AS Debt-to-Equity Chart

Exact Therapeutics AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.03

Exact Therapeutics AS Semi-Annual Data
	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial						0.02	0.02	0.03	0.03	0.03

Competitive Comparison of Exact Therapeutics AS's Debt-to-Equity

For the Biotechnology subindustry, Exact Therapeutics AS's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exact Therapeutics AS's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exact Therapeutics AS's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Exact Therapeutics AS's Debt-to-Equity falls into.

Exact Therapeutics AS Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Exact Therapeutics AS's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.546	+	0.65)	/	45.101
	=	0.03

Exact Therapeutics AS's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.546	+	0.65)	/	45.101
	=	0.03

Exact Therapeutics AS (OSL:EXTX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Exact Therapeutics AS Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Exact Therapeutics AS's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Exact Therapeutics AS (OSL:EXTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exact Therapeutics AS (OSL:EXTX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ostre Aker vei 19, Oslo, NOR, 0581

Website

https://www.exact-tx.com

Exact Therapeutics AS is a clinical-stage biotechnology company. It is developing a technology platform for therapeutic enhancement - Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement that will amplify the clinical utility of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions.

Exact Therapeutics AS (OSL:EXTX) Headlines

No Headlines